Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia

Acta Haematologica

Volumn 102, Issue 3, 1999, Pages 160-162

  Lacotte, L ^a   Thierry, A ^a   Delwail, V ^a   Dreyfus, B ^a   Guilhot, F ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic myelogenous leukemia; Immunologic effects; Interferon alpha; Thrombotic thrombocytopenic purpura

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PLASMA TRANSFUSION; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED DISORDER; MONOCYTIC LEUKEMIA;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MONOCYTIC, CHRONIC; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 0033631716     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040993     Document Type: Article

References (16)

1. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
2. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-916.
3. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991;114:532-538.
4. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J, for the French Chronic Myeloid Leukemia Study Group: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229.
5. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomized, multicentre trial of interferon-α n l for chronic mycloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995;345: 1392-1397.
6. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4:234-243.
7. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clarck JW: Exacerbation of symptoms of autoimmune disease in patients receiving α-interferon therapy. Cancer 1990;65: 2237-2242.
8. Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome. Am J Hematol 1994;46: 152-153.
9. Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, Altal M, Laurent G, Pris J: Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994;47:254-255.
10. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM: Thrombotic microangiopathy (TM) associated with interferon therapy in chronic myelogenous leukemia (CML): Coincidence or a true side effect? (abstract). Blood 1998;92(suppl 1):4064.
11. Rachmani R, Avigdor A, Youkla M, Raanani P, Zilber M, Ravid M, Ben-Bassat I: Thrombotic thrombocytopenic purpura complicating chronic myclogenous leukemia treated with interferon-α. Acta Haematol 1998;100:204-206.
12. Teichmann J, Siebber G, Ludwig W, Ruchl H: Immunosuppressive effects of recombinant IFN-α during long-term treatment of cancer patients. Cancer 1989;63:1990-1993.
13. Carlson K., Smedmyr B, Hagberg H, Öberg G, Simonsson B: Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-c, cyclophosphamide) versus TBI and autologous BMT for malignant lymphomas. Bone Marrow Transplant 1993; 11:205-208.
14. Shammas F, Meyer P, Heikkila R, Apeland T, Goransson L, Berland J, Kjellevold K: Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Acta Haematol 1997;97:184-186.
15. Nield GH: Hemolytic-uremic syndrome in practice. Lancet 1994;143:398-401.
16. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer L, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.